Related Articles
ANCA-Associated Vasculitis Trial Results May Change Standard of Care
SNOWMASS VILLAGE, COLO.—The study of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is ongoing, and research results should help improve treatment for this patient population. Key trials and therapeutic options were discussed at the 2020 ACR Winter Symposium during the session, Update on the Treatment of ANCA-Associated Vasculitis, by Peter A. Merkel, MD, MPH, chief of…
Good Flow: 2021 Updates in Vasculitis
During the ACR Convergence 2021 annual Review Course, Peter Merkel, MD, MPH, provided recent updates on vasculitis.
Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis
Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.
Maintenance of Remission in ANCA-Associated Vasculitis
Relapses are common, but difficult to predict and prevent.